ERBB2 and neoplasm: Emerging solutions, such as dual-target CAR-T cells that simultaneously recognize two tumor-associated antigens (e.g., HER2/MUC1 or B7-H3/CD276), aim to counter antigen escape, enhance specificity, and reduce off-tumor toxicity [13, 14].